Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.

This oversubscribed Series A funding round was led by General Catalyst with additional investment from new investors, British ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...